1. Home
  2. NTRA vs CCEP Comparison

NTRA vs CCEP Comparison

Compare NTRA & CCEP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Natera Inc.

NTRA

Natera Inc.

N/A

Current Price

$272.94

Market Cap

56.7B

Sector

Health Care

ML Signal

N/A

Logo Coca-Cola Europacific Partners plc

CCEP

Coca-Cola Europacific Partners plc

N/A

Current Price

$115.55

Market Cap

51.0B

ML Signal

N/A

Company Overview

Basic Information
Metric
NTRA
CCEP
Founded
2003
1986
Country
United States
United Kingdom
Employees
N/A
N/A
Industry
Medical Specialities
Beverages (Production/Distribution)
Sector
Health Care
Consumer Staples
Exchange
Nasdaq
Nasdaq
Market Cap
56.7B
51.0B
IPO Year
2015
2015

Fundamental Metrics

Financial Performance
Metric
NTRA
CCEP
Price
$272.94
$115.55
Analyst Decision
Strong Buy
Buy
Analyst Count
23
13
Target Price
★ $412.36
$113.29
AVG Volume (30 Days)
★ 2.0M
1.5M
Earning Date
11-05-2026
08-04-2026
Dividend Yield
N/A
★ 2.19%
EPS Growth
★ 0.65
N/A
EPS
N/A
★ N/A
Revenue
★ $210,939,000.00
N/A
Revenue This Year
$30.72
$3.77
Revenue Next Year
$21.67
$4.29
P/E Ratio
★ N/A
$20.93
Revenue Growth
N/A
★ N/A
52 Week Low
$181.00
$84.66
52 Week High
$437.41
$120.41

Technical Indicators

Market Signals
Indicator
NTRA
CCEP
Relative Strength Index (RSI) 24.66 53.69
Support Level $254.83 $90.22
Resistance Level $288.04 $119.09
Average True Range (ATR) 19.03 2.27
MACD -7.70 -0.38
Stochastic Oscillator 1.47 46.70

Price Performance

Historical Comparison
NTRA
CCEP

About NTRA Natera Inc.

Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.

About CCEP Coca-Cola Europacific Partners plc

CCEP is the second-largest bottling partner in the Coca-Cola system by volume, behind Coca-Cola Femsa, and primarily operates in developed Europe, Australasia, and Southeast Asia. In 2025, CCEP sold 3.9 billion unit cases of beverages, which we estimate equates to roughly 9% of the global Coke system volume.TCCC owns 19% of the equity of CCEP, Olive Partners, a holding company of bottling operations, owns a further 36%, and the remaining 45% is free float.

Share on Social Networks: